Such studies might highlight the potential suitability of LGR5 as a target antigen for the CAR-T therapy of ovarian cancer, as well as colorectal cancer; however, such CAR-T products need to be thoroughly and strictly evaluated in clinical settings to substantiate such claims. The gene discussed is LGR5; the disease is colorectal cancer.